MedTrace Logo

Red Bull Energy Drink Intake After Autologous Microsurgical Breast Reconstruction

NCT04397419 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-04-25

No results posted yet for this study

Summary

The success rate of autologous microsurgical breast reconstruction depends on adequate intraoperative and postoperative flap perfusion. Perfusion is optimized intraoperatively by a full hyperdynamic circulation and maintenance of a normal body temperature. Additional safe and simple postoperative measures to guarantee adequate perfusion pressure would be desirable. Recently, the effect of Red Bull® Energy Drink on cardiovascular and renal function, pain tolerance as well as performance has been studied in clinical trials involving healthy volunteers and athletes. Notably, an increase in blood pressure, heart rate, improved endothelial function and reduced pain perception have been observed. A better understanding of its effects in patients undergoing autologous microsurgical breast surgery would be of great value. When ingested in standard amounts, Red Bull® Energy Drink has been shown to be a safe beverage without notable side effects. The investigators prospectively study the effect of postoperative oral ingestion of Red Bull® Energy Drink on perfusion-related variables and patient recovery after autologous microsurgical breast reconstruction.

Conditions

Interventions

DIETARY_SUPPLEMENT

Red Bull Energy Drink

The intervention group receives 250 ml Red Bull Energy Drink 2-3 hours after surgery and 500 ml on postoperative day 1. Regimen: * 2-3 hours after surgery: 250 ml * Postoperative day 1: morning and noon (1-1-0-0) 250 ml

OTHER

Still water

The control group receives 250 ml still water 2-3 hours after surgery and 500 ml on postoperative day 1. Regimen: * 2-3 hours after surgery: 250 ml * Postoperative day 1: morning and noon (1-1-0-0) 250 ml

Sponsors & Collaborators

  • Plastic Surgery Group AG by Prof. Jian Farhadi

    lead OTHER

Principal Investigators

  • Jian Farhadi, M.D., Prof. · University of Basel, Plastic Surgery Group AG by Prof. Jian Farhadi, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2022-12-01
Completion
2023-01-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397419 on ClinicalTrials.gov